<DOC>
	<DOCNO>NCT01018875</DOCNO>
	<brief_summary>Efficacy safety study ABT-288 adult mild-to-moderate Alzheimer 's disease .</brief_summary>
	<brief_title>Efficacy Safety Study ABT-288 Subjects With Mild-to-Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>1 . Have voluntarily sign informed consent . 2 . Subject meet diagnostic criterion criterion probable AD ( Alzheimer 's Disease ) . 3 . Female subject must postmenopausal least 2 year surgically sterile . 4 . Male subject must surgically sterile , sexually inactive use barrier method birth control . 5 . Subject identify , reliable caregiver . 6 . Subject CT MRI scan within 36 month prior randomization . 7 . With exception diagnosis mildtomoderate AD presence stable medical condition , subject generally good health base medical history , physical examination , vital sign , clinical lab test ECG 1 . Subject currently take take medication treatment AD dementia 60 day Screening visit , participate cognitive therapy treatment AD dementia . 2 . Subject us nonprescribed drug abuse history drug alcohol abuse/dependence . 3 . Subject history significant neurologic disease AD . 4 . Subject history intolerance adverse reaction donepezil lead discontinuation . 5 . Subject received investigation product within 6 week prior study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>